Indonesia Pharmaceutical Market Outlook to 2022
By Therapeutic Segment (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology), By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region
Region:Asia
Product Code:KR587
February 2018
118
About the Report
The report titled "Indonesia Pharmaceutical Market Outlook to 2022 - By Therapeutic Segment (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology), By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region" provides information on market size for Indonesia Healthcare and pharmaceutical.
Indonesia Pharmaceutical Market: Indonesia Pharmaceutical market has registered an increase in the revenue at a CAGR of ~% from USD ~ billion in 2012 to USD ~ billion in 2017.
By Therapeutic Segment: Anti-infective drug sale has contributed to the largest share of ~% in the revenue share of Indonesia Pharmaceutical industry in 2017. This is mainly due to high prevalence of bacterial and communicable diseases. This is followed by Gastrointestinal and metabolism drugs with ~%, cardiovascular system drugs with ~%, Central Nervous system drugs with ~%, Respiratory system drugs with ~%, Musculoskeletal system drugs with ~%, dermatology drugs with ~%, genitourinary and hormonal drugs with ~%, blood related drugs with ~%, oncology with ~% and rest of the therapeutic segments with ~% of the revenue share in 2017.
By Domestic and International Players: Domestic players have accounted for ~% of the revenue in Indonesia pharmaceutical market in 2017 driven by the implementation of JKN (National Health Insurance System) in 2014. International players have captured ~% of the revenue share in 2017 driven by favorable government norms for foreign ownership.
By Generic and Patented Drug: Generic drugs have accounted for the major revenue share of ~% in 2017 driven by the increased demand from government run hospitals and clinics. The share of patented drugs has increased from ~% in 2013 to ~% in 2017. Further, ethical generic drugs have accounted for ~% of the Indonesia generic drug market revenue in 2017 followed by free sale drugs with ~% and unbranded drug sale with ~%.
By OTC and Prescription Drugs: The Prescription drugs sales have accounted for ~% of the revenue share in Indonesia Pharmaceuticals Market. OTC drugs have accounted for ~% of the revenue share in 2017. This segment is driven by increased tendency of Indonesians to treat them and take self medication
By Domestic Sales and Exports: Domestic sales have accounted for a majority revenue share of ~% in 2017 whereas exports have accounted for a small share of ~%. The domestic market is dominated by the sale of low priced ethical generic medicines.
Indonesia Pharmaceutical Market Competition Overview: Indonesia Pharmaceutical market is dominated by domestic players which control ~% of the market in 2017. Recent favorable government regulations have facilitated the entry of foreign players in the space. There are 206 pharmaceutical companies (182 domestic and 24 international companies) located in Indonesia and ~% of them are located in Java in 2016. These players compete on the basis of distribution network, product portfolio, marketing activities and research and development. The domestic players dominate the generic drug and over the counter drug segment. International players have better expertise, skilled labor and infrastructure to produce such medicines at competitive prices. While domestic companies dominate the market for low cost generic drugs, multinational players have taken over high-demand, specialized segments and pharmaceuticals services ranging from capsule provision to instrumentation and packaging.
Indonesia Pharmaceutical Market Future Potential: Indonesia pharmaceutical industry is expected to increase from USD ~ billion in 2018 to USD ~ billion at a growth rate of ~%. The industry growth will be led by Indonesia’s large population and growing middle-income class, supportive government policies and higher investment in the industry. With the increase in incidence of communicable diseases such as HIV, TB, therapeutic segments such as anti infectives and respiratory are expected to grow. Major companies are expected to increase investment in nutritional and herbal medicines due to changing preference in the industry. Apart from manufacturing generic and patented drugs, pharmaceutical companies will shift focus to other niche segments such as combined dosages, novel drug delivery areas. Further in order to overcome the shortcomings, Contract Development and Manufacturing Organizations (CDMOs) will emerge as an attractive resource for manufacturers seeking to expand their capacities.
Key Topics Covered in the Report:
-
Indonesia Healthcare Market Size, 2012-2017
-
Indonesia Pharmaceutical Market Size, 2012-2017
-
Indonesia Pharmaceutical Market Segmentation (by therapeutic segment, by domestic & international players, by generic & patented drug, by OTC & prescription drugs, by domestic sales & exports and by region)
-
Trends and Developments in Indonesia Pharmaceutical Market
-
Issues and Challenges in Indonesia Pharmaceutical Market
-
Government Initiatives, Rules and Regulations in Indonesia Pharmaceutical Market
-
Indonesia Pharmaceutical Market Competitive Landscape
-
Indonesia Pharmaceutical Future Outlook and Projections, 2018-2022
-
Indonesia Healthcare Future Outlook and Projections, 2018-2022
-
Analyst Recommendations
-
Macro-economic Factors Impacting Indonesia Healthcare Market
Products
Companies
- PT Kalbe Farma,
- PT Sanbe Farma,
- PT SOHO Global Health,
- PT Dexa Medica,
- PT Pharos,
- PT Kimia Farma,
- PT Tempo Scan Pacific Tbk,
- PT Merck Tbk,
- Fahrenheit,
- Sanofi Aventis,
- PT. Novell Pharmaceutical Laboratories,
- Biofarma,
- Darya Varia and Konimex
Table of Contents
1. Executive Summary
Indonesia Healthcare Market Overview
Indonesia Pharmaceutical Market Segmentation
Indonesia Pharmaceutical Market Competition Overview
Indonesia Pharmaceutical Market Future Potential
2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
2.3. Market Size and Modeling
Consolidated Research Approach
Market Sizing – Pharmaceutical Market
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
3. Indonesia Healthcare Market Size, 2012-2017
4. Indonesia Pharmaceutical Market Introduction
4.1. Indonesia Pharmaceutical Market Size, 2012-2017
5. Indonesia Pharmaceutical Market Segmentation, 2017
5.1. By Therapeutic Segments (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology and Others), 2015 & 2017
Vitamins and Dietary Supplements Market, 2012-2017
5.2. By Domestic and International Players, 2012-2017
5.3. By Generic and Patented Drug, 2017
By Type of Generic Drugs (Unbranded, Ethical and Free Sales), 2013 and 2017
5.4. By OTC and Prescription Drugs, 2012-2017
5.5. By Domestic Sales and Exports, 2012-2016
5.6. By Region (West Java, East Java, Central Java, Jakarta and Others), Dec 2016
6. Trends, Developments and Restraint in Indonesia Pharmaceutical Market
Growth in Indonesia Animal Pharmaceutical and Vaccine Market
Increased Government Support
Rise in Mergers and Acquisitions Activities
Growing Investment from Foreign Companies
Dependence on Imports for API (Active Pharmaceutical ingredient) Procurement
Other Challenges Faced
7. Government Regulations for Indonesia Pharmaceutical market
Pharmaceutical Finished Products Registration Requirement
Registration Procedure
Pharmaceutical Raw Materials
Advertising and Distribution
FDI in Pharmaceutical Industry
Procedure of Applying for Patent in Indonesia
Import Regulations
Draft Law on Monitoring of Pharmaceutical Supply, Medical Devices and Household Health Products
Draft law on Hala Product Guarantee
Regulations for Non-Indonesian Stakeholders Planning to Enter the Pharmaceutical Market
8. Indonesia Biopharmaceutical Industry Snapshot
Innogene Kalbiotech
9. Snapshot on Indonesia Vaccine Market
10. Competitive Scenario for Major Players in Indonesia Pharmaceutical Market
10.1. Market Share of Major Players in Indonesia Pharmaceutical Market, 2015
11. Competitive Landscape of Major Players in Indonesia Pharmaceutical Market
11.1. PT Kalbe Farma
Product Portfolio for PT Kalbe Farma
11.2. PT Sanbe Farma
Product Portfolio for PT Sanbe Farma
11.3. PT SOHO Global Health
11.4. PT Dexa Medica
Product Portfolio for Dexa Medica
11.5. PT Pharos
Product Portfolio for PT Pharos
11.6. PT Kimia Farma
Product Portfolio for PT Kimia Farma
11.7. PT Tempo Scan Pacific Tbk
Product Portfolio for PT Tempo Scan Pacific Tbk, Indonesia
11.8. PT Merck Tbk
11.9. Overview for Other Major Players (Fahrenheit, Sanofi Aventis, PT. Novell Pharmaceutical Laboratories, Biofarma, Darya Varia and Konimex) in Indonesia Pharmaceutical Market
12. Indonesia Pharmaceutical Market Future Outlook and Projections, 2018-2022
12.1. By Therapeutic Segments (Anti Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology and Others), 2022
12.2. By Generic and Patent Drugs, 2022
13. Analyst Recommendations
14. Macro Economic Factors Affecting Indonesia Healthcare Market
14.1. Population, 2012-2022
14.2. Number of Health Centers, 2012-2022
14.3. Budget Allocation on Healthcare, 2012-2022
14.4. Obese Population, 2012-2022
Disclaimer
Contact Us
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.